Skip to main content
Clinical and Vaccine Immunology : CVI logoLink to Clinical and Vaccine Immunology : CVI
. 2014 Jul;21(7):1021. doi: 10.1128/CVI.00314-14

Comparison of Four Commercial One-Dose Porcine Circovirus Type 2 (PCV2) Vaccines Administered to Pigs Challenged with PCV2 and Porcine Reproductive and Respiratory Syndrome Virus at 17 Weeks Postvaccination To Control Porcine Respiratory Disease Complex under Korean Field Conditions

Changhoon Park 1, Hwi Won Seo 1, Kiwon Han 1, Chanhee Chae 1
PMCID: PMC4097445

AUTHOR CORRECTION

Volume 21, no. 3, p. 399–406, 2014. Page 399, column 2: Lines 10–17 should read as follows. “… Four commercial PCV2 vaccines were administered intramuscularly in the right side of the neck at 3 weeks of age at different dosages according to the manufacturer's instructions: 2.0 ml of inactivated chimeric PCV1–2 vaccine (Fostera PCV; Zoetis, Madison, NJ) (group 1), 0.5 ml of inactivated PCV2 vaccine (Circovac; Merial, Lyon, France) (group 2), 1.0 ml of PCV2 subunit A vaccine (Circoflex; Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO) (group 3), and 2.0 ml of PCV2 subunit B vaccine (Porcilis PCV; MSD Animal Health, Boxmeer, The Netherlands) (group 4)….”


Articles from Clinical and Vaccine Immunology : CVI are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES